Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.
Novo Nordisk used a solid Q4 update to confirm it will progress its investigative once-weekly basal insulin to Phase III.
Sanofi’s Q4 update will highlight planned strategic changes and Dupixent’s key growth role, amid a strong rebound in quarterly US flu vaccine sales.
Ozempic's continued good growth and the ongoing roll out of oral Rybelsus should revitalize growth and expand Novo's reach in the diabetes market this year.